Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Lilly on Thursday reported fourth-quarter revenue of $13.53 billion, a steep 45% increase over the sum the Indianapolis-based drugmaker generated during the same period in 2023.

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled ... download and connect to the short video app through package kits on its website, in an effort to circumvent restrictions ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations." "2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday ... Technologycategory TikTok to let US Android users download app via kits on its website 2:57 AM UTC ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...

Like many other biopharma companies presenting at this year’s J.P. Morgan Healthcare Conference, Eli Lilly took a chance on Tuesday to share its preliminary sales results for 2024. Unfortunately ...